Excited to have Praveen Tipirneni, CEO of Morphic Therapeutic, join us on the latest episode! With a focus on developing transformative treatments for autoimmune diseases, Morphic Therapeutic is making significant strides in the biotech industry. In this episode hosted by Rahul Chaturvedi, Founder and CEO of Clora, Praveen shares insights into the current state of autoimmune therapies and Morphic's innovative approaches, including their pioneering work on oral integrin inhibitors. He also discusses his extensive experience in corporate development and strategy, highlighting the importance of building strong teams and fostering a culture of excellence. Tune in for an insightful discussion on the future of autoimmune treatment and the role of Morphic Therapeutic in shaping it! Listen now: https://lnkd.in/g6ftzSDt #Biotech #AutoimmuneTherapies #Innovation #Leadership #Healthcare #Podcast #Biotech2050
Biotech2050’s Post
More Relevant Posts
-
🎧The latest episode of our Let's Talk Rare podcast is now live! In this episode, Georgie and Owen are joined by their colleagues Pina (Josephina) Haberl, who is a Senior Director, and Sam Morrison, who is the Executive Director at Partners4Access. Join us as we discuss the crucial role of patient experience data in drug development. Here are some key talking points from the show: ✅ Patient experience data can inform drug development, improve clinical trials, and differentiate products in the market. Collecting patient data can be challenging due to reluctance and lack of awareness. Early involvement and listening to patients is crucial. 📋 Regulators and HTA bodies are starting to accept patient experience data, but its use is inconsistent. Collaboration is key to establishing best practices for utilizing patient experience data. 🤝 Let's bring together industry, policymakers, and patient groups. And we’re just getting warmed up! Tune in via the links below: Podcast Link: https://lnkd.in/d9mFYPND #P4AInsights #letstalkrare #podcast #patientexperiencedata
To view or add a comment, sign in
-
Delighted to unveil the newest #Biotech 2050 episode with Marshall Fordyce, M.D. Fordyce, the innovative Founder & CEO of Vera Therapeutics, Inc.! 🎙️ In this episode, Host Rahul Chaturvedi joins Marshall as they delve into his transformative journey from physician to biotech entrepreneur, offering invaluable perspectives on the biotech industry. Discover how Vera Therapeutics pivoted to focus on IG nephropathy and their groundbreaking work with atacicept, a promising B-cell modulator. Key highlights include: 🔹 The importance of scientific rigor and adaptability 🔹 Navigating the biotech landscape 🔹 Future outlook on autoimmune disease treatments Whether you're an aspiring entrepreneur or a seasoned professional, Marshall's insights on maintaining a lean operating model and driving innovation are a must-listen. 🎧 Tune in now and get inspired by the future of autoimmune disease treatments: https://lnkd.in/eaq7isNN #Biotech #Autoimmune #Innovation #Healthcare #BiotechBreakthroughs #Podcast #MedicalResearch #ClinicalTrials #DrugDevelopment #HealthcareInnovation #Entrepreneurship
To view or add a comment, sign in
-
Check out the new episode of Biotech2050, hosted by Clora CEO, Rahul Chaturvedi, where he welcomes back former guest Marshall Fordyce, M.D., the Founder & CEO of Vera Therapeutics, Inc., after two years. In this episode, Marshall delves into Vera Therapeutics' strategic pivot from an initial gene editing platform to autoimmune and rare kidney diseases, specifically the story of atacicept as a dual BAFF/APRIL B cell modulator for IgA Nephropathy (IgAN), a B cell-mediated kidney disease that often progresses to kidney failure. Leveraging a value-creating lens, Marshall provides key insights into the importance of scientific rigor in biotech, adapting to the evolving biotech landscape, and maintaining a lean and effective operating model. Don't miss out on this must-listen episode! Tune in using the link below. #Clora #podcast #biotech #entrepreneur #leadership #autoimmunedisease #drugdevelopment #IgAN #kidneydisease
Delighted to unveil the newest #Biotech 2050 episode with Marshall Fordyce, M.D. Fordyce, the innovative Founder & CEO of Vera Therapeutics, Inc.! 🎙️ In this episode, Host Rahul Chaturvedi joins Marshall as they delve into his transformative journey from physician to biotech entrepreneur, offering invaluable perspectives on the biotech industry. Discover how Vera Therapeutics pivoted to focus on IG nephropathy and their groundbreaking work with atacicept, a promising B-cell modulator. Key highlights include: 🔹 The importance of scientific rigor and adaptability 🔹 Navigating the biotech landscape 🔹 Future outlook on autoimmune disease treatments Whether you're an aspiring entrepreneur or a seasoned professional, Marshall's insights on maintaining a lean operating model and driving innovation are a must-listen. 🎧 Tune in now and get inspired by the future of autoimmune disease treatments: https://lnkd.in/eaq7isNN #Biotech #Autoimmune #Innovation #Healthcare #BiotechBreakthroughs #Podcast #MedicalResearch #ClinicalTrials #DrugDevelopment #HealthcareInnovation #Entrepreneurship
To view or add a comment, sign in
-
🎧 💊 Hear life science industry practitioners share how they’re leveraging supply chain best practices and resources to secure access to life-saving cancer immunotherapies for patients. Listen to the #RethinkingResilience podcast from Resilinc: https://okt.to/Oov64W #lifesciences #supplychain #riskmanagement
Podcast | The life sciences supply chain: Insights around drug shortages, production capacity and speed to market
https://www.resilinc.com
To view or add a comment, sign in
-
Go-to-Market Strategy | Chief Product and Marketing Officer | Growth Leader | Advisor | Holistic Health & Wellbeing Advocate
🎧 💊 Hear life science industry practitioners share how they’re leveraging supply chain best practices and resources to secure access to life-saving cancer immunotherapies for patients. Listen to the #RethinkingResilience podcast from Resilinc: https://okt.to/gxpGJH #lifesciences #supplychain #riskmanagement
Podcast | The life sciences supply chain: Insights around drug shortages, production capacity and speed to market
https://www.resilinc.com
To view or add a comment, sign in
-
Digital Marketer & Process Improvement NERD - I help companies improve their systems and processes, amplify their voice, increase awareness and drive leads.
In our latest episode of the Life Science Success Podcast, we had the privilege of hosting Donald Zinn, Vice President of US Business - BD&L at Crossject . With nearly three decades in the life sciences industry, Don brings a wealth of knowledge and experience to the table, discussing the groundbreaking needle-free auto injector technology that's set to revolutionize patient care. Here's what we covered: 🌟 Donald Zinn's Journey: From pioneering in biotechnology to leading innovations at Crossject, Don shares his expansive career journey and the lessons learned along the way. 💉 Needle-Free Auto Injector: A look into Crossject's innovative solution designed to alleviate needle phobia and ensure medications can be administered quickly and safely. 🤝 Strategic Partnerships: Insight into how Crossject is navigating partnerships globally to bring this essential technology to markets worldwide. 🔍 The Future of Healthcare: Discussion on the potential impact of needle-free technology in improving patient outcomes and adherence. 📈 Entrepreneurship and Innovation: Don's take on the importance of innovation in healthcare and how to foster a culture of creativity and problem-solving. This episode is a must-listen for anyone interested in the cutting-edge of medical device technology, healthcare innovation, and the future of patient care. Whether you're a professional in the life sciences, a healthcare provider, or simply someone passionate about the advancement of healthcare technology, you'll find invaluable insights and inspiration from Don's story. 🎧 Listen to the full episode to get inspired and learn more about the technology that could change the way we think about drug delivery. https://lnkd.in/gabgZYCX #LifeSciences #DrugDeliveryTechnology #HealthcareInnovation #Biotechnology #Pharmaceuticals #EntrepreneurshipInLifeSciences #PatientCareImprovement #StartupPartnerships #MedicalDevices #ProfessionalDevelopment
Donald Zinn - Vice President US Business - BD&L - Crossject
lifesciencesuccess.com
To view or add a comment, sign in
-
Digital Marketer & Process Improvement NERD - I help companies improve their systems and processes, amplify their voice, increase awareness and drive leads.
🌟 In our first episode of 2024, we had the incredible opportunity to dive deep into the world of immunology and T-cell therapy with two distinguished guests from Virax Biolabs - CEO James Foster and COO Nigel McCracken. 🔬 James Foster, a visionary leader and co-founder of Virax Biolabs, shared his fascinating journey from finance to biotech. He discussed the company's mission to revolutionize immune profiling with their cutting-edge "Viru Immune" platform, aiming to tackle the growing challenges of post-viral syndromes and chronic inflammation. 🌐 Nigel McCracken, with his extensive experience, shed light on the operational complexities and strategic growth of Virax. His insights on the development of companion diagnostics are a must-hear for anyone interested in the future of personalized medicine. 💡 Key Takeaways: The importance of early detection in disease management. The role of innovation and execution in scaling biotech ventures. The growing need for effective diagnostics in the face of long COVID and chronic conditions. 🤝 Join us in this enlightening conversation and discover how Virax Biolabs is shaping the future of healthcare. Don't forget to share your thoughts and insights in the comments below! #LifeScienceSuccess #ViraxBiolabs #Immunology #BiotechInnovation #HealthcareFuture #TCellTherapy #PodcastHighlight #LeadershipInsights #PersonalizedMedicine #BiotechCommunity
James Foster CEO & Nigel McCracken COO - Virax Biolabs
lifesciencesuccess.com
To view or add a comment, sign in
-
Our Co- Founder and CEO, John Catanzaro sat down with Dr. Nathan Goodyear to discuss the new ideas that may reshape modern medicine in the newest episode of Dr. Goodyear’s podcast. Collaborations such as these are what accelerate the ability to find modern cures that are centered around the individualized therapeutics approach. Dr. Goodyear also acts as a scientific advisor to Neo7Bioscience. Dr. Goodyear has helped many patients with the use Neo7s individualized peptides in his clinic Brio- Medical located in Arizona. Find the podcast here: https://lnkd.in/giGMtQkM #podcast #medicine #doctors #peptides #peptide
To view or add a comment, sign in
-
-
Obesity, affecting millions in the Western world, especially in the US with a nearly 40% prevalence, is a key focus for both pharma and biotech investors. In this episode, Joel Sendek and Jay Olson discuss recent developments in treating obesity, upcoming therapies, and key companies to watch. Tune in today! This episode is available on all major #podcast platforms. https://bit.ly/3Gl3Dvc #Oppenheimer #LetsTalkFuture #Obesity #Biotech #NewTherapies
New Obesity Treatments on the Horizon: Biotech Stocks to Watch
To view or add a comment, sign in
-
Senior and Executive Search Specialist | Building Leadership Teams for Technology Growth in MedTech, BioTech, Pharma & HealthTech | Life Sciences & STEM
🔬 Big news in the biotech world! 🌟 AltruBio's strategic decision to pivot towards immune drug research has truly paid off. Not only have they secured a remarkable Series B round of up to $225M, but also their mid-stage drug for ulcerative colitis is showing great potential. 💥 A sharp turn from cancer to immunology has placed them right at the heart of one of the most dynamic sectors in drug development today. The investment wave in inflammatory disease research is tangible, and it's exciting to see AltruBio riding it with confidence and expertise. 💡 For decision-makers in MedTech and BioTech, AltruBio stands as a testament to the power of agility and the foresight in the ever-evolving healthcare landscape. Their journey from rebranding and leadership change to now leading the charge in immune disease therapy is definitely one to watch. For my executive peers leading tech initiatives, AltruBio's story is an inspiration. It demonstrates the impact of strategic innovation and adaptability in achieving breakthroughs that resonate across industries. #Biotech #Innovation #HealthcareTech
AltruBio lands up to $225M after shift to immune drug research
To view or add a comment, sign in